Trump's MFN Policy May Disrupt Global Drug Pricing, Impact India
| Key Aspect | Details |
|---|---|
| Event | US President Donald Trump announces "Most Favoured Nation" (MFN) executive order |
| Date | May 12, 2025 |
| Objective | Ensure Americans pay no more for prescription drugs than the lowest global price |
| Expected US Impact | Reduction in drug prices by 30-80% |
| Global Impact | Potential rise in drug prices in low-cost markets like India |
| Indian Pharma Role | India is a leading supplier of generic drugs to the US and UK |
| Indian Concerns | Pressure to raise drug prices to avoid low benchmarks under MFN |
| Indian Legal Framework | Complies with WTO's TRIPS, protects access to affordable medicines |
| Industry Response | Indian generic exporters may not suffer directly, but margins could shrink |
| US Market Composition | 79% patented drugs, 21% generics |
| Market Reaction | Sharp decline in Indian pharma stocks over margin concerns |
| Global Pharma Strategy | May push for price alignment across countries |